<DOC>
	<DOCNO>NCT02522975</DOCNO>
	<brief_summary>This study aim comprehensively establish biosimilarity/bioquivalence EPIAO® EPREX® term 52-week comparison efficacy , safety immunogenicity.The target population anaemia patient chronic renal disease naive epoetin treatment yet haemodialysis .</brief_summary>
	<brief_title>Biosimilar Erythropoietin Anaemia Treatment ( Correction Phase Study )</brief_title>
	<detailed_description>This prospective , randomize , double blind , parallel group two arm study establish therapeutic equivalence , safety tolerability EPIAO® compare EPREX® treatment CKD relate anaemia subject yet dialysis ( pre-dialysis ) . A total 96 subject randomize two group 1:1ratio . Treatment arm A receive EPIAO® week , subcutaneously period 52 week treatment arm B receive EPREX , weight week , subcutaneously period 52 week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Male female subject age 18 75 year 2 . Subjects renal anaemia ( haemoglobin 7.5 g/dl 10 g/dl ) 3 . Subjects treatment naïve epoetin 4 . Subjects chronic kidney disease ( CKD ) stages* 3 4 yet dialysis ( predialysis ) 5 . Subjects willing provide write informed consent 6 . Subjects serum ferritin ≥ 100 μg/L and/or transferrin saturation ≥ 20 % CKD staging base fivestage system classification CKD base KDIGO guideline . 1 . Subjects anaemia due reason ( renal anaemia ) 2 . Subjects dialysis 3 . Subjects undergone blood transfusion within last 3 month 4 . Subjects major complication severe/chronic infection bleed , aluminum toxicity 5 . Subjects suspect know PRCA 6 . Subjects history aplastic anaemia 7 . Subjects uncontrolled diabetes ( fast blood glucose &gt; 240 mg/dl ) uncontrolled hypertension ( systolic blood pressure &gt; 180 mm Hg , diastolic blood pressure &gt; 110 mm Hg ) 8 . Subjects know hypersensitivity ingredient investigational product , mammalian cellderived product human albumin product 9 . Subjects history seizure disorder 10 . Subjects hematological disorder ( thrombocytopenia , neutropenia , hemolysis ) 11 . Subjects hyperparathyroidism ( intact parathyroid hormone &gt; 1000 pg/ml ) 12 . Subjects severe liver dysfunction 13 . Subjects congestive heart failure and/or angina ( NYHA class III IV ) 14 . Subjects myocardial infarction stroke precede 6 month screen 15 . Subjects active malignancy previous 5 year 16 . Subjects gastrointestinal bleeding past 6 month 17 . Subjects immunosuppressive therapy previous 3 month 18 . Subjects Hepatitis B virus ( HbsAg ) , Hepatitis C virus ( HCV ) , Human Immunodeficiency Virus ( HIV ) syphilis 19 . Female subject pregnant , breastfeeding , plan pregnant study , woman childbearing potential ( woman surgically sterile i.e . bilateral tubal ligation , total hysterectomy &lt; 2 year post menopause ) use reliable method double contraception ( e.g . condom plus diaphragm , condom diaphragm plus spermicidal gel/foam , tubal ligation , stable dose hormonal contraception ) throughout study period 20 . Subjects participate trial involve erythropoietin past 6 month screen 21 . Subjects currently participate participation investigational study within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>biosimilar epoetin</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>renal anaemia</keyword>
</DOC>